MMSL 2024, 93(1):10-18 | DOI: 10.31482/mmsl.2023.022

HISTOLOGICAL ASSESSMENT OF REMDESIVIR ON KIDNEY AND LIVER OF ALBINO RATS IN DIFFERENT DOSES AND THEIR WITHDRAWALOriginal article

Rana M. Ahmad ORCID...*, Maha Al-Sammak ORCID...
Department of Anatomy, College of Medicine, University of Mosul, Mosul, Iraq

Background: Remdesivir has recently been used more widely as an antiviral medication, possibly due to its potency against coronavirus.

Aim: This study was aimed at detecting the toxicity of remdesivir on the liver and kidneys of albino rats at various doses, as well as the possibility of recovering to the normal structure of these tissues two weeks after drug discontinuation.

Methods: Forty adult albino rats were divided into five groups (8 rats per group). The first group was the control group; the second group received 5 mg/kg remdesivir; the third group received 10 mg/kg for five days; and the fourth and fifth groups were withdrawal groups (treated as 2nd and 3rd groups then left for two weeks). After five days of treatment, the animals of the 1st, 2nd, and 3rd groups were sacrificed, while the animals of the withdrawal groups were killed after two weeks of drug discontinuation. Both the liver and kidneys were removed and prepared for histological examination.

Results: Remdesivir-treated liver and kidneys showed histological alterations such as blood vessel congestion, mononuclear cell infiltration, and localized hepatocyte degeneration. Meanwhile, kidney sections revealed localized vacuolation of the tubular epithelium, focal glomerular tuft shrinkage with Bowman's space dilatation.

Conclusion: Remdesivir is hepatotoxic and nephrotoxic mainly, at high doses. Even after drug withdrawal, structural alterations persist, particularly at high dosages, confirming that remdesivir toxicity is dose-dependent.

Keywords: Remdesivir; Remdesivir withdrawal; Histological changes

Received: January 13, 2023; Revised: April 18, 2023; Accepted: May 12, 2023; Prepublished online: May 31, 2023; Published: March 1, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ahmad, R.M., & Al-Sammak, M. (2024). HISTOLOGICAL ASSESSMENT OF REMDESIVIR ON KIDNEY AND LIVER OF ALBINO RATS IN DIFFERENT DOSES AND THEIR WITHDRAWAL. MMSL93(1), 10-18. doi: 10.31482/mmsl.2023.022
Download citation

References

  1. Prajapat M, Sarma P, Shekhar N, et al. Update on the target structures of SARS-CoV-2: A systematic review. Indian Journal of Pharmacology. 2020;52(2):142. https://doi.org/10.4103/ijp.IJP_338_20. Go to original source... Go to PubMed...
  2. Darweesh O, Abdulrazzaq GM, Al-Zidan RN, et al. Evaluation of the Pharmacologic Treatment of COVID-19 Pandemic in Iraq. Current Pharmacology Reports. 2021;7(4):171-178. https://doi.org/10.1007/s40495-021-00262-9 Go to original source... Go to PubMed...
  3. Zhang Y, Geng X, Tan Y, et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomedicine & pharmacotherapy. 2020;127:110195. https://doi.org/10.1016/j.biopha.2020.110195 Go to original source... Go to PubMed...
  4. Paranjpe I, Russak AJ, De Freitas JK, et al. Clinical characteristics of hospitalized COVID-19 patients in New York City. MedRxiv. 2020. https://doi.org/10.1136/bmjopen-2020-040736 Go to original source... Go to PubMed...
  5. Matos RI, Chung KK. DoD COVID-19 practice management guide: clinical management of COVID-19. Defense Health Agency Falls Church United States; 2020 Jun 18.
  6. Chan KW, Wong VT, Tang SCW. COVID-19: an update on theepidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2020;13:1-26. https ://doi.org/10.1142/S0192 415X2 05003 78. Go to original source...
  7. Ansems K, Grundeis F, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database of Systematic Reviews. 2021(8). https://doi.org/10.1002/14651858.CD014962 Go to original source... Go to PubMed...
  8. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The lancet. 2020;395(10236):1569-1578. Go to original source... Go to PubMed...
  9. Arundel C, Lewis JH. Drug-induced liver disease in 2006. Current opinion in gastroenterology. 2007;23(3):244-254. Go to original source... Go to PubMed...
  10. Leegwater E, Strik A, Wilms EB, et al. Drug-induced liver injury in a patient with coronavirus disease 2019: Potential interaction of remdesivir with P-Glycoprotein inhibitors. Clinical Infectious Diseases. 2021;72(7):1256-1258. https://doi.org/10.1093/cid/ciaa883 Go to original source... Go to PubMed...
  11. Dale AP, Hudson MJ, Cullen T, et al. Administration of bamlanivimab to skilled nursing facility residents during a COVID-19 outbreak, January-February 2021, Arizona. Journal of the American Medical Directors Association. 2021;22(7):1357-1358. https://doi.org/10.1016/j.jamda.2021.04.023 Go to original source... Go to PubMed...
  12. Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int. 2020;1-3. https://doi.org/10.1007/s12072-020- 10077-3. Go to original source... Go to PubMed...
  13. Li J, Fan JG. Characteristics and mechanism of liver injury in 2019 coronavirus disease. Journal of Clinical and Translational Hepatology. 2020;8(1):13. https://doi.org/10.14218/JCTH.2020.00019 Go to original source... Go to PubMed...
  14. Fan Q, Zhang B, Ma J, et al. Safety profile of the antiviral drug remdesivir: An update. Biomedicine & Pharmacotherapy. 2020;130:110532. https://doi.org/10.1016/j.biopha.2020.110532 Go to original source... Go to PubMed...
  15. Ison MG, Wolfe C, Boucher HW. Emergency use authorization of remdesivir: the need for a transparent distribution process. Jama. 2020;323(23):2365-2366. https://doi.org/10.1001/jama.2020.8863 Go to original source... Go to PubMed...
  16. Yang K. What do we know about remdesivir drug interactions?. Clinical and translational science. 2020;13(5):842. https://doi.org/10.1111/cts.12815 Go to original source... Go to PubMed...
  17. Stella VJ, Rajewski RA. Sulfobutylether-β-cyclodextrin. Int J Pharm. 2020;583:119396. https://doi.org/10.1016/j. ijpharm.2020.119396. Go to original source... Go to PubMed...
  18. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. New England Journal of Medicine. 2020;382(24):2327-2336. https://doi.org/10.1056/NEJMoa2007016. Go to original source... Go to PubMed...
  19. Wong CK, Au IC, Cheng WY, et al. Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: A self-controlled case series study. Alimentary Pharmacology & Therapeutics. 2022. https://doi.org/10.1111/apt.16894. Go to original source... Go to PubMed...
  20. Abdulqader SW, Faisal IM, Saeed MG, et al. Fluvoxamine Provide a Gastro-Protection Against Vitiated Insult. Indian Journal of Forensic Medicine & Toxicology. 2022;16(1):1047. https://doi.org/10.37506/ijfmt.v16i1.17633 Go to original source...
  21. Abdulqader SW, Faisal IM, Saeed MG, et al. Fluvoxamine Suppressed Oxidative Stress associated with Tissue Erosion. Research Journal of Pharmacy and Technology. 2022;15(2):819-824. https://doi.org/10.52711/0974-360X.2022.00136. Go to original source...
  22. Suvarna SK, Layton C, Bancroft JD, John D (2013). Bancroft's Theory and Practice of Histological Techniques. 7th ed., Churchill Livingstone, Elsevier Limited ,UK, pp:215-236. Go to original source...
  23. McGrowder DA, Miller F, Anderson Cross M, et al. Abnormal liver biochemistry tests and acute liver injury in COVID-19 patients: current evidence and potential pathogenesis. Diseases. 2021;9(3):50. https://doi.org/10.20944/preprints 20210.0552. Go to original source... Go to PubMed...
  24. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver international. 2020;40(5):998-1004. https://doi.org/10.1111/liv.14435. Go to original source... Go to PubMed...
  25. van Laar SA, de Boer MG, Gombert-Handoko KB, et al. LUMC-COVID-19 Research Group. Liver and kidney function in patients with COVID-19 treated with remdesivir. British journal of clinical pharmacology. 2021;87(11):4450-4454. https://doi.org/10.1111/bcp.14831. Go to original source... Go to PubMed...
  26. Hala El-Haroun , Manar Ali Bashandy, Mona Soliman. Impact of Remdesivir on the kidney and Potential Protective Capacity of Granulocyte-Colony Stimulating Factor Versus Bone Marrow Mesenchymal Stem Cells in Adult Male Albino Rats. Egyptian journal of Histology. 2022;45(2):338-358. https://doi.org/10.21608/ejh.2021.60527.1426. Go to original source...
  27. Lo MK, Feldmann F, Gary JM, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Science translational medicine. 2019;11(494): eaau9242. https://doi.org/10.1126/scitranslmed.aau9242 Go to original source... Go to PubMed...
  28. Kevin L, Valerie G, Michael P, et al. Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19. ACG Case Reports Journal. 2022; 9(10):p e00866. https://doi.org/10.14309/crj.0000000000000866 Go to original source... Go to PubMed...
  29. Wang S, Huynh Ch, D'Andrea Joseph D. Assessment of Safety of Remdesivir in Covid - 19 Patients with Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min per 1.73 m^2. Journal of Intensive Care Medicine. 2021;37(6). https://doi.org/10.1177/08850666211070521. Go to original source... Go to PubMed...
  30. Nasir H, Raja KM, Satti Sh, et al. Safety of Remdesivir in Covid Patients with Acute or Chronic Kidney Disease. Ann Pak Inst Med Sci. 2022;18(4):300-303. https://doi.org/10.48036/apims.v18i4.668. Go to original source...
  31. Goldman JD, Lye DC, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. New England Journal of Medicine. 2020;383(19):1827-1837. https://doi.org/10.1056/NEJMoa2015301. Go to original source... Go to PubMed...
  32. Korovila I, Höhn A, Jung T, et al. Reduced liver autophagy in high-fat diet induced liver steatosis in New Zealand obese mice. Antioxidants. 2021;10(4):501. http://doi.org/10.3390/antiox 10040501. Go to original source... Go to PubMed...
  33. Sharma DJ, Deb A, Sarma P, et al. Comparative Safety and Efficacy of Remdesivir Versus Remdesivir Plus Convalescent Plasma Therapy (CPT) and the Effect of Timing of Initiation of Remdesivir in COVID-19 Patients: An Observational Study From North East India. Cureus. 2021;13(11). https://doi.org/10.7759/cureus.19976. Go to original source... Go to PubMed...
  34. Sharm Harkars. Overiew on Remdesivir international Journal of Science and Research, 2021;10(6). https://doi.org/1/10.21275/MR 21620233.
  35. Piscoya A, Ng-Sueng LF, Parra del Riego A, et al. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. PloS one. 2020;15(12):e0243705. https://doi.org/10.1371/journal.pone.0243705 Go to original source... Go to PubMed...
  36. Rahimi MM, Jahantabi E, Lotfi B, et al. Renal and liver injury following the treatment of COVID-19 by remdesivir. Journal of Nephropathology. 2021;10(2):1-4. https://doi.org/10.34172/jnp.2021.10 Go to original source...
  37. Shephard MT, Merkhan MM, Forsyth NR. Human Mesenchymal Stem Cell Secretome Driven T Cell Immunomodulation Is IL-10 Dependent. International Journal of Molecular Sciences. 2022;23(21):13596. https://doi.org/10.3390/ijms232113596 Go to original source... Go to PubMed...
  38. Narayanasamy KK, Price JC, Merkhan M, et al. Cytotoxic effect of PEI-coated magnetic nanoparticles on the regulation of cellular focal adhesions and actin stress fibres. Materialia. 2020;13:100848. https://doi.org/10.1016/j.mtla.2020.100848 Go to original source...
  39. Merkhan MM, Shephard MT, Forsyth NR. Physoxia alters human mesenchymal stem cell secretome. Journal of Tissue Engineering. 2021;12:20417314211056132. https://doi.org/10.1177/20417314211056132. Go to original source... Go to PubMed...
  40. Forsyth NR, Steeg R, Ahmad M, et al. Mimicking Physiological Oxygen in Cell Cultures. InCell Culture Technology 2018 (pp. 129-137). Springer, Cham. https://doi.org/10.1007/978-3-319-74854-2_8. Go to original source...